US pharma major Eli Lilly shares closed up 2.8%, while those of Adverum Biotechnologies dropped 2.4% to $4.28, on news of a ...
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Adverum Biotechnologies, Inc. (NasdaqCM: ADVM) ...
Against the backdrop of global trade policy uncertainties, even the threat of high tariffs may not be able to stop the upward momentum of certain high-quality stocks. Taking pharmaceutical giant ...
Inhibrx said the encouraging results in treating the rare, slow growing cancer that often begins in the bone, bolster its plans to file a BLA in the second quarter of 2026. The company’s stock (NASDAQ ...
Our firm litigates and has recovered money for shareholders…and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in ...
U .S. pharmaceutical giant Eli Lilly (LLY) is acquiring gene therapy developer Adverum Biotechnologies (ADVM) in a deal ...
The Ademi Firm is investigating Adverum for possible breaches of fiduciary duty and other violations of law in its transaction with Eli ...
Lilly’s upfront offer for Adverum, the developer of a gene therapy for age-related macular degeneration, is less than the ...
Wall Street saw a relief rally as cooler-than-estimated inflation reinforced trader conviction on Federal Reserve ...
Eli Lilly and Company announced a definitive agreement to acquire Aderum Biotechnologies and its leading candidate Ixo-vec. 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback